Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Viral Hepatitis Data From AASLD 2020 – Rapid Recap

November 13-16, 2020; Virtual
Hear insights from Norah Terrault, MD, MPH, on some of the most important viral hepatitis data reported at the virtual American Association for the Study of Liver Diseases (AASLD) 2020 annual meeting, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.
Norah Terrault Headshot
Norah Terrault, MD, MPH
Released: November 25, 2020

In this episode, Dr. Terrault discusses results from key viral hepatitis studies reported at the American Association for the Study of Liver Diseases (AASLD) 2020 annual conference, The Liver Meeting Digital Experience, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.

Presenter:

Norah Terrault, MD, MPH
Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by
Gilead Sciences

Related Content

Download this PDF guide outlining key information on HCC risk assessment, screening, and surveillance in the setting of Hepatitis B infection

Robert S. Brown, Jr., MD, MPH Released: February 22, 2021

Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection

Paul Y. Kwo, MD Released: February 18, 2021

Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

Download free expert-authored slides reviewing AASLD guidance on HBV management pretreatment evaluation to determine treatment candidacy

Paul Y. Kwo, MD Released: February 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue